<?xml version="1.0" encoding="UTF-8"?>
<p>Severe acute respiratory syndrome is a viral respiratory disease of zoonotic origin caused by SARS-CoV. The SARS outbreak between November 2002 and July 2003 resulted in 8098 cases and 774 deaths in 29 countries around the world, giving a case-fatality rate of 9.6%.
 <xref rid="b7-dic-2020-4-15" ref-type="bibr">7</xref>,
 <xref rid="b8-dic-2020-4-15" ref-type="bibr">8</xref> Treatments for SARS during the outbreak were mainly supportive, as there were no known effective antiviral agents. The use of broad-spectrum antibiotics to treat secondary bacterial infections was the main treatment regimen.
 <xref rid="b9-dic-2020-4-15" ref-type="bibr">9</xref> Ribavirin, a broad-spectrum purine nucleoside analogue, was empirically used as a broad-spectrum antiviral agent.
 <xref rid="b10-dic-2020-4-15" ref-type="bibr">10</xref> Human immunodeficiency virus (HIV) protease inhibitor lopinavir/ritonavir were also used, as it was found to have weak 
 <italic>in vitro</italic> antiviral activity on the prototype SARS-CoV.
 <xref rid="b10-dic-2020-4-15" ref-type="bibr">10</xref>,
 <xref rid="b11-dic-2020-4-15" ref-type="bibr">11</xref> Other therapies included immunomodulators (e.g. corticosteroid, convalescent plasma, and pentaglobulin), interferons, and traditional Chinese medicine (TCM).
 <xref rid="b9-dic-2020-4-15" ref-type="bibr">9</xref>,
 <xref rid="b12-dic-2020-4-15" ref-type="bibr">12</xref> The development of vaccines was underway by the end of the epidemic, but no effective vaccine has since emerged.
</p>
